Rxsight Stock Today
| RXST Stock | USD 46.40 0.34 0.74% |
Performance0 of 100
| Odds Of DistressLess than 38
|
Rxsight is selling for under 46.40 as of the 28th of November 2024; that is 0.74 percent increase since the beginning of the trading day. The stock's last reported lowest price was 46.11. Rxsight has about a 38 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Rxsight are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of October 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 30th of July 2021 | Category Healthcare | Classification Health Care |
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses used in cataract surgery in the United States and internationally. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California. The company has 40.3 M outstanding shares of which 2.74 M shares are at this time shorted by private and institutional investors with about 5.07 trading days to cover. More on Rxsight
Moving against Rxsight Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Rxsight Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Ronald MD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsRxsight can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Rxsight's financial leverage. It provides some insight into what part of Rxsight's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rxsight (RXST) is traded on NASDAQ Exchange in USA. It is located in 100 Columbia, Aliso Viejo, CA, United States, 92656 and employs 374 people. Rxsight is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.86 B. Rxsight conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 40.3 M outstanding shares of which 2.74 M shares are at this time shorted by private and institutional investors with about 5.07 trading days to cover.
Rxsight currently holds about 128.62 M in cash with (41.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.65.
Check Rxsight Probability Of Bankruptcy
Ownership AllocationRxsight owns a total of 40.3 Million outstanding shares. The majority of Rxsight outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Rxsight to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Rxsight. Please pay attention to any change in the institutional holdings of Rxsight as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Rxsight Ownership Details
Rxsight Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Divisadero Street Capital Management, Lp | 2024-09-30 | 773.6 K | |
| State Street Corp | 2024-06-30 | 755.3 K | |
| Bank Of America Corp | 2024-06-30 | 755.3 K | |
| Driehaus Capital Management Llc | 2024-06-30 | 706.2 K | |
| Gilder Gagnon Howe & Co Llc | 2024-09-30 | 586.5 K | |
| Nuveen Asset Management, Llc | 2024-06-30 | 559.1 K | |
| Brown Capital Management, Llc | 2024-09-30 | 542.4 K | |
| Next Century Growth Investors Llc | 2024-06-30 | 528.3 K | |
| No Street Gp Lp | 2024-09-30 | 475 K | |
| Ra Capital Management, Llc | 2024-09-30 | 3.9 M | |
| Blackrock Inc | 2024-06-30 | 2.4 M |
Rxsight Historical Income Statement
Rxsight Stock Against Markets
Rxsight Corporate Management
| Matt Haller | Chief Officer | Profile | |
| Alex Huang | Investor Relations | Profile | |
| Oliver Moravcevic | Vice Relations | Profile | |
| Scott Gaines | Senior Process | Profile | |
| Caroline Vaughn | Vice Resources | Profile |
Additional Tools for Rxsight Stock Analysis
When running Rxsight's price analysis, check to measure Rxsight's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rxsight is operating at the current time. Most of Rxsight's value examination focuses on studying past and present price action to predict the probability of Rxsight's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rxsight's price. Additionally, you may evaluate how the addition of Rxsight to your portfolios can decrease your overall portfolio volatility.